Sort   by:  
 Page size 
The receptor tyrosine kinase EPHA2 has gained interest as therapeutical drug target in cancer and infectious diseases in the past years. However, EPHA2 research and EPHA2 based therapies have been hampered by the lack of selective small molecule EPHA2 inhibitors. We report on the synthesis and evalu...
ORGANISM(S): Homo sapiens (Human) 
2017-05-30 | PXD006193 | Pride
The receptor tyrosine kinase EPHA2 plays important roles in oncogenesis, metastasis and treatment resistance but therapeutic targeting, drug discovery or investigation of EPHA2 biology is hampered by the lack of appropriate inhibitors and structural information on how these interact with the protein...
ORGANISM(S): Homo sapiens (Human) 
2016-12-23 | PXD004112 | Pride
The mitotic kinase Aurora-A is essential for cell cycle progression and considered a priority cancer target. Dozens of ongoing clinical trials are testing the anti-cancer potential of Aurora-A kinase inhibitors. While the catalytic activity of Aurora-A is essential for its function during mitosis, a...
ORGANISM(S): Homo sapiens (Human) 
2020-09-28 | PXD019585 | Pride
The phosphatases PP1 and PP2A are responsible for the majority of dephosphorylation reactions on phosphoserine (pS) and –threonine (pT), and are involved in basically all cellular processes and many related diseases. They are thought to have no appreciable intrinsic substrate specificity, but to gai...
ORGANISM(S): Homo sapiens (Human) 
2020-07-14 | PXD012026 | Pride
The locus of heat resistance (LHR) confers extreme heat resistance in E. coli. This study explored the role of the LHR in pressure resistance of E. coli, as well as its relationship with protein folding and aggregation in vivo. The role of LHR was investigated in E. coli MG1655 expressing a ibpA-yfp...
ORGANISM(S): Escherichia coli 
2020-01-27 | PXD011023 | Pride
Gastric cancer (GC) represents a major health problem, remaining the fifth most common type of cancer and the third leading cause of cancer-related death worldwide with only few targeted therapies available to date. The positive effect of kinase inhibitors on many different types of cancers has prom...
ORGANISM(S): Homo sapiens (Human) 
2020-05-26 | PXD012953 | Pride
The oncogene MYC drives many cancers and is an outstanding therapeutic target. MYC is an intrinsically disordered protein, and therefore, targeting MYC remains a challenge. Here, we developed a proteolysis targeting chimera (PROTAC) degrading MYC: MDEG-541. The inhibitor is based on the MYC-MAX dim...
ORGANISM(S): Homo sapiens (Human) 
2022-05-12 | PXD018674 | Pride
EPHrin receptors (EPH) are transmembrane receptor tyrosine kinases. Their extracellular domains bind specifically to ephrin A/B ligands, and this binding modulates the intracellular kinase activity. EPHs are key players in bidirectional intercellular signalling, controlling cell morphology, adhesion...
ORGANISM(S): Homo sapiens (Human) 
2018-09-05 | PXD009188 | Pride
Evaluation of kinase binding to immobilized inhibitors upon kinase activation. Comparison of cheomproteomic binding changes to phosphoproteomic activation profiles.
ORGANISM(S): Homo Sapiens (ncbitaxon:9606) 
2016-10-21 | MSV000080272 | MassIVE
Most molecular cancer therapies act on protein targets but data on the proteome status of patients and cellular models are only beginning to emerge. Here, we profiled the proteomes of 65 colorectal cancer (CRC) cell lines to a depth of >10,000 proteins using mass spectrometry. Integration with prote...
ORGANISM(S): Homo Sapiens (ncbitaxon:9606) 
2017-11-23 | MSV000081738 | MassIVE
Sort   by:  
 Page size